Human A Proliferation-Inducing Ligand (APRIL)

<strong>Human A Proliferation-Inducing Ligand (APRIL)</strong>_x000D_ <strong>Catalog number:</strong> B2018550_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> ~19 kDa_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> −20°C_x000D_ <strong>Keywords:</strong> APRIL_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Myette JR, Kano T, Suzuki H, Sloan SE, Szretter KJ, Ramakrishnan B, Adari H, Deotale KD, Engler F, Shriver Z, Wollacott AM, Suzuki Y, Pereira BJG. A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy Kidney Int. 2019 Jul;96(1):104-116._x000D_ 2: Cai J, Gao D, Liu D, Liu Z. Telitacicept for autoimmune nephropathy Front Immunol. 2023 Jun 5;14:1169084._x000D_ 3: Dhillon S. Telitacicept: First Approval Drugs. 2021 Sep;81(14):1671-1675._x000D_ 4: Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, Sahay M, Suzuki Y, Wong MG, Yarbrough J, Xia J, Pereira BJG; ENVISION Trial Investigators Group. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy N Engl J Med. 2024 Jan 4;390(1):20-31._x000D_ 5: Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease Immunopharmacol Immunotoxicol. 2021 Dec;43(6):666-673._x000D_ 6: Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity Cytokine Growth Factor Rev. 2013 Jun;24(3):203-15._x000D_ 7: Samy E, Wax S, Huard B, Hess H, Schneider P. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases Int Rev Immunol. 2017 Jan 2;36(1):3-19._x000D_ 8: Wu L, Du X, Lu X. Role of telitacicept in the treatment of IgA nephropathy Eur J Med Res. 2023 Sep 22;28(1):369._x000D_ 9: Fan Y, Gao D, Zhang Z. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus Drugs Today (Barc). 2022 Jan;58(1):23-32._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/33184844">10: Uzawa A, Kuwabara S, Suzuki S, Imai T, Murai H, Ozawa Y, Yasuda M, Nagane Y, Utsugisawa K. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis Clin Exp Immunol. 2021 Mar;203(3):366-374. </a>_x000D_ _x000D_ <strong>Products Related to Human A Proliferation-Inducing Ligand (APRIL) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>